» Articles » PMID: 35677298

Biomimetic Exosomes: A New Generation of Drug Delivery System

Overview
Date 2022 Jun 9
PMID 35677298
Authors
Affiliations
Soon will be listed here.
Abstract

Most of the naked drugs, including small molecules, inorganic agents, and biomacromolecule agents, cannot be used directly for disease treatment because of their poor stability and undesirable pharmacokinetic behavior. Their shortcomings might seriously affect the exertion of their therapeutic effects. Recently, a variety of exogenous and endogenous nanomaterials have been developed as carriers for drug delivery. Among them, exosomes have attracted great attention due to their excellent biocompatibility, low immunogenicity, low toxicity, and ability to overcome biological barriers. However, exosomes used as drug delivery carriers have significant challenges, such as low yields, complex contents, and poor homogeneity, which limit their application. Engineered exosomes or biomimetic exosomes have been fabricated through a variety of approaches to tackle these drawbacks. We summarized recent advances in biomimetic exosomes over the past decades and addressed the opportunities and challenges of the next-generation drug delivery system.

Citing Articles

Leveraging nature's nanocarriers: Translating insights from extracellular vesicles to biomimetic synthetic vesicles for biomedical applications.

Chen Y, Douanne N, Wu T, Kaur I, Tsering T, Erzingatzian A Sci Adv. 2025; 11(9):eads5249.

PMID: 40009680 PMC: 11864201. DOI: 10.1126/sciadv.ads5249.


Mesenchymal Stem-Cell-Derived Exosomes as Novel Drug Carriers in Anti-Cancer Treatment: A Myth or Reality?.

Harrell C, Volarevic A, Djonov V, Volarevic V Cells. 2025; 14(3).

PMID: 39936993 PMC: 11817634. DOI: 10.3390/cells14030202.


Research progress of mosquito-borne virus mRNA vaccines.

Sun N, Su Z, Zheng X Mol Ther Methods Clin Dev. 2025; 33(1):101398.

PMID: 39834558 PMC: 11743085. DOI: 10.1016/j.omtm.2024.101398.


Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges.

Ruchi R, Raman G, Kumar V, Bahal R Expert Opin Drug Discov. 2024; 20(1):63-80.

PMID: 39653607 PMC: 11823135. DOI: 10.1080/17460441.2024.2440095.


Edge advances in nanodrug therapies for osteoarthritis treatment.

Liao J, Gu Q, Liu Z, Wang H, Yang X, Yan R Front Pharmacol. 2024; 15:1402825.

PMID: 39539625 PMC: 11559267. DOI: 10.3389/fphar.2024.1402825.


References
1.
Antimisiaris S, Mourtas S, Marazioti A . Exosomes and Exosome-Inspired Vesicles for Targeted Drug Delivery. Pharmaceutics. 2018; 10(4). PMC: 6321407. DOI: 10.3390/pharmaceutics10040218. View

2.
Jiang W, Ma P, Deng L, Liu Z, Wang X, Liu X . Hepatitis A virus structural protein pX interacts with ALIX and promotes the secretion of virions and foreign proteins through exosome-like vesicles. J Extracell Vesicles. 2020; 9(1):1716513. PMC: 7006762. DOI: 10.1080/20013078.2020.1716513. View

3.
Gyorgy B, Sage C, Indzhykulian A, Scheffer D, Brisson A, Tan S . Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV. Mol Ther. 2017; 25(2):379-391. PMC: 5368844. DOI: 10.1016/j.ymthe.2016.12.010. View

4.
Min Y, Caster J, Eblan M, Wang A . Clinical Translation of Nanomedicine. Chem Rev. 2015; 115(19):11147-90. PMC: 4607605. DOI: 10.1021/acs.chemrev.5b00116. View

5.
El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View